MAPT and Alzheimer disease: Moreover, additional preclinical studies should address the potential of 3OMQ in chronic models of AD, including transgenic mice models, to address the impact of this compound on other landmark features of the disease, including synapse loss, tau phosphorylation and aggregation, Aβ accumulation, and neuronal death.